CCOP Goals and Objectives (2009-2014) The overall goal of MeritCare Hospital CCOP is to provide state-of-the-art cancer care to patients and families, as close to home as possible, through the participation in National Cancer Institute (NCI) approved clinical trials. Program Objectives: 1) Increase the number of eligible patients place on NCI approved cancer treatment clinical research trials. 2) Facilitate wider community participation, including minorities, women, and other underserved populations in cancer treatment, prevention, and control research approved by NCI. 3) Continue to enhance the participation of primary healthcare providers and other specialist with the CCOP investigators in cancer treatment and control research. 4) Increase the quality and efficiency of data management systems/processes. 5) Expand participation in NCI approved cancer prevention and control clinical research trials.

Public Health Relevance

Over 1.4 million new cancer cases are expected to be diagnosed in the United States in 2008 with approximately 565,650 cancer related deaths. Cancer is the second most common cause of death in the United States, exceeded only by heart disease. In the United States, cancer accounts for 1 of every 4 deaths.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037417-30S1
Application #
8850961
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Good, Marge
Project Start
1983-09-30
Project End
2014-07-31
Budget Start
2014-06-01
Budget End
2014-07-31
Support Year
30
Fiscal Year
2014
Total Cost
$13,466
Indirect Cost
$5,154
Name
Sanford Research/Usd
Department
Type
DUNS #
050113252
City
Sioux Falls
State
SD
Country
United States
Zip Code
57104
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Pruthi, Sandhya; Qin, Rui; Terstreip, Shelby A et al. (2012) A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 19:48-53
Bolton, John S; O'Connell, Michael J; Mahoney, Michelle R et al. (2012) Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer 11:31-7
Wolf, Sherry L; Barton, Debra L; Qin, Rui et al. (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625-32

Showing the most recent 10 out of 124 publications